$MAZE
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Healthcare
Sector
Biotechnology
Industry
Jason V. Coloma
CEO
125
Employees
$26.46
Current Price
$2.17B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $190,299.00 | 7,500 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 11 | $1,662,272.23 | 47,500 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 3 | 17 | $3,742,566.29 | 90,000 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Apr 29, 2026 | Dandekar Atul CSBO | Sale | 7,500 | $25.37 | $190,299.00 | View Details |
| Apr 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 11,352 | $29.24 | $331,948.37 | View Details |
| Apr 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 300 | $31.07 | $9,320.01 | View Details |
| Apr 1, 2026 | Bernstein Harold President, R&D & CMO | Sale | 3,348 | $30.06 | $100,635.86 | View Details |
| Apr 1, 2026 | Bachrodt Amy SVP, Finance | Sale | 300 | $30.34 | $9,101.01 | View Details |
| Apr 1, 2026 | Bachrodt Amy SVP, Finance | Sale | 2,200 | $29.32 | $64,509.94 | View Details |
| Mar 30, 2026 | Dandekar Atul CSBO | Sale | 790 | $30.02 | $23,713.67 | View Details |
| Mar 30, 2026 | Dandekar Atul CSBO | Sale | 6,710 | $29.26 | $196,305.08 | View Details |
| Mar 20, 2026 | Bernstein Harold President, R&D & CMO | Sale | 6,161 | $48.20 | $296,976.83 | View Details |
| Mar 20, 2026 | Bernstein Harold President, R&D & CMO | Sale | 3,795 | $49.32 | $187,168.64 | View Details |
| Mar 20, 2026 | Bernstein Harold President, R&D & CMO | Sale | 5,044 | $50.02 | $252,293.82 | View Details |
| Mar 10, 2026 | Bernstein Harold President, R&D & CMO | Sale | 29,652 | $50.45 | $1,495,807.00 | View Details |
| Mar 10, 2026 | Bernstein Harold President, R&D & CMO | Sale | 348 | $51.02 | $17,753.22 | View Details |
| Feb 27, 2026 | Dandekar Atul CSBO | Sale | 3,739 | $45.13 | $168,756.03 | View Details |
| Mar 2, 2026 | Bachrodt Amy SVP, Finance | Sale | 3,700 | $45.47 | $168,236.78 | View Details |
| Mar 2, 2026 | Bachrodt Amy SVP, Finance | Sale | 1,300 | $44.44 | $57,773.82 | View Details |
| Feb 27, 2026 | Dandekar Atul CSBO | Sale | 3,761 | $45.72 | $171,967.21 | View Details |
27 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.71
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.69
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.69
ActualN/A
Revenue
EstimatedN/A
ActualN/A
EPS
Estimated-$0.68
ActualN/A
Revenue
EstimatedN/A
ActualN/A
2 more earnings records available โ create a free account to see 12 months of history